Clinical Trials
57 trialsKEYLYNK-001
Merck Sharp & Dohme LLC
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
KEYNOTE-B96
Merck Sharp & Dohme LLC
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
MK-4830-002
Merck Sharp & Dohme LLC
KEYVIBE-005
Merck Sharp & Dohme LLC
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
PRESERVE-001
OncoC4, Inc.
IVY
Eli Lilly and Company
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Canadian Cancer Trials Group
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
Barbara Ann Karmanos Cancer Institute
Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
University of Wisconsin, Madison
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
National Cancer Institute (NCI)
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Dana-Farber Cancer Institute
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
GOG Foundation
Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Yale University
IP
University of Louisville
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
Masonic Cancer Center, University of Minnesota
Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
Wake Forest University Health Sciences
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
SWOG Cancer Research Network
Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma
Washington University School of Medicine
LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma
University of Miami
Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Hoosier Cancer Research Network
Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer
M.D. Anderson Cancer Center
Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
GOG Foundation
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
University of Arizona
Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma
Hellenic Oncology Research Group
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
Duke University
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
Merck Sharp & Dohme LLC
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
SWOG Cancer Research Network
Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma
University of Southern California
Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Chemotherapy in Treating Patients With Solid Tumors
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
National Cancer Institute (NCI)
Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
M.D. Anderson Cancer Center
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
GOG Foundation
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
National Institutes of Health Clinical Center (CC)
Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
Azaya Therapeutics, Inc.
TEACO
Sanofi
OCSTUD
Sanofi
Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
Dana-Farber Cancer Institute
Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
Montefiore Medical Center